Evidence of past infection with Epstein-Barr virus (EBV) and smoking are well-known risk factors for multiple sclerosis (MS). These 2 exposures together also are risk factors for several cancers, including nasopharyngeal carcinoma (NPC) 1, 2 and Hodgkin lymphoma (HL). 3, 4 For these diseases, EBV and smoking may be independent risk factors, 1 associated with different histologic types 2, 4 that have different prognoses. Yet other research suggests a biological interaction between EBV infection and smoking for HL. 3 Smoking may itself influence EBV infection. For example, EBV DNA (as a marker of EBV replication) was more likely to be detected in oral epithelial cells of HIV-infected individuals who smoke than in nonsmokers, 5 and in a Danish (non-MS) population sample, 6 smoking was associated with increased anti-EBV viral capsid antigen titers with a dose-response relationship for number of smoking pack-years, and a stronger effect in women.
In this issue of Neurology ® , Sundqvist et al. 7 examined whether the combination of ever-smoking and higher EBV nuclear antigen (EBNA) titers increased the risk of MS beyond what would be expected if each factor was acting independently of the other. They found that ever-smoking and higher EBNA-1 titers were independent risk factors for MS, with no evidence of interaction on either an additive or multiplicative scale. These results differ from previous studies that have shown multiplicative interactions that have been both positive 8 -that is, increased risk associated with higher EBNA titer was particularly strong in ever-smokers (odds ratio [OR] 3.9, 95% confidence interval [CI] 2.7-5.7 compared to never-smokers: OR 1.8, 95% CI 1.4 -2.3)-as well as negative, 9 where the increased MS risk associated with a past history of infectious mononucleosis was higher in nonsmokers (OR 2.4, 95% CI 1.8 -3.2 compared to smokers: OR 1.6, 95% CI 1.3-2.1). Additionally, in one of these studies, 8 the increased MS risk associated with smoking was seen only among those who had high anti-EBNA titers. 8 How can we reconcile these results? First, there are differences in study design. Simon et al. 8 used pooled data from the Nurses' Health Cohort Studies (women only), the Tasmanian MS Study (a population-based case-control study of prevalent MS cases), and the Swedish MS Study (a registrybased case-control study of prevalent MS cases). The 3 studies had different data collection regimens, particularly in the timing of data collection (including blood) in relation to disease onset, and different methods of measuring anti-EBNA titers, requiring transformation to be comparable across studies. The study by Riise et al. 9 used history of infectious mononucleosis as the measure of EBV infection (rather than antibody titers) in a large multinational casecontrol study that included participants from Italy, Norway, Sweden, Serbia, and Canada. The Sundqvist et al. 7 work in this issue of Neurology is perhaps the strongest study design, being based on a single, large population-based case-control study of newly diagnosed MS cases from all over Sweden, with measurement of EBNA-1 immunoglobulin G (IgG) levels on a single assay.
There are additionally minor differences in the form of analysis. Simon et al. 8 used a conditional logistic regression following matching on age and sex; Riise et al. 9 adjusted for age and sex (with an unspecified analytic technique); Sundqvist et al. 7 report the results of both logistic and conditional logistic regressions. The latter makes use of the initial matching on age and sex to remove any possible confounding effect of these factors. However, since not all matched controls returned complete data, the logistic regression, adjusting for age and sex, allows for more complete use of the data, but with the possibility of some residual confounding. Results from the conditional logistic regression are suggestive of a stronger MS risk in association with past EBV infection in never-smokers (compared to ever-smokers), similar to the findings by Riise et al., 9 but both multiplicative and additive interactions are nonsignifi-cant. Simon et al. 8 used a smoking classification of current, past, never; Riise et al. 9 smoker/nonsmoker; Sundqvist et al., 7 ever-smoker/never-smoker. These latter differences may have influenced the results, if the proportions of current smokers vs past smokers differed across the "ever-smoker" category, with current smoking possibly of particular importance to current measurements of anti-EBNA IgG, if an interaction truly exists. Participants in the Sundqvist et al. 7 study were also younger, more recently diagnosed, and therefore less likely to have modified their lifestyle in response to diagnosis. Each or any of these factors could have contributed to the discrepant results.
What is the relevance of the findings? Multiplicative interaction implies interacting biological pathways, e.g., smoking alters the likelihood of EBV infection or modulates the host immune response to EBV infection. In this case, the association between EBNA IgG titer and MS risk would have a different slope depending on smoking status. There are some indications to support such biological interactions, 5, 8 but no definitive evidence exists either to support or refute its importance for MS risk. An additive interaction implies that the risk attributable to having the 2 factors is greater than the sum of the risks associated with each factor separately. Additive interaction provides information about the attributable proportion, that is, the proportion of disease can be attributed to the presence of either or both factors (and thus avoided if either or both factors are minimized).
Sundqvist et al. also report that higher EBNA-1 titers and presence of DRB1*15 genotype or absence of A*02 genotype interacted on an additive scale to increase MS risk, consistent with some, 10 but not all, 8 previous studies. Further, the combination of 4 risk factors (smoking, high EBNA-1, DRB1*15 positive, A*02 negative) was associated with a 26-fold increase in risk of MS compared to having none of these factors.
There are no clear-cut answers from these studies in relation to interactions between EBV infection and smoking. There is now the full range reported of positive interaction, no interaction, and negative interaction, with the discrepancies possibly related to the type of data collected, the study design, or the statistical methodology. Nevertheless, one clear and consistent message is that smoking is a risk factor for MS, and this should be modifiable with the support of clinicians, to decrease risk of onset, and possibly progression, in MS.
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